Open AccessSevere Generalized Pustular Psoriasis Successfully Treated with Ixekizumab: A Case Report
Author(s) -
Burlando Martina,
Salvi Ilaria,
Paravisi Andrea,
Cozzani Emanuele,
Parodi Aurora
Publication year - 2022
Publication title -
case reports in dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.338
H-Index - 18
ISSN - 1662-6567
DOI - 10.1159/000526037
Subject(s) - single case
Generalized pustular psoriasis (GPP) is a severe and potentially life-threatening type of psoriasis. We present the case of a patient with severe GPP, at first unsuccessfully treated with cyclosporine. We chose to treat the patient with ixekizumab, an anti-IL-17 antibody known for its rapid action in psoriasis vulgaris, that has also been reported as effective in GPP. The patient improved rapidly, with resolution of the active lesions after the first administration. The treatment has been continued for 2 years, with no adverse events and sustained disease control. Ixekizumab could be considered a safe and effective option in patients with GPP.